What is HC Wainwright’s Forecast for PepGen Q1 Earnings?

PepGen Inc. (NASDAQ:PEPG) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of PepGen in a research note issued on Monday, February 24th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.75) for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.74) EPS.

A number of other equities analysts also recently commented on PEPG. Bank of America downgraded shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a report on Monday, December 16th. Wedbush reduced their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, November 8th.

PepGen Trading Down 25.3 %

Shares of PEPG opened at $1.71 on Wednesday. The firm has a market cap of $55.75 million, a price-to-earnings ratio of -0.57 and a beta of 1.53. PepGen has a 52 week low of $1.16 and a 52 week high of $19.30. The stock has a 50 day moving average of $2.46 and a 200-day moving average of $5.78.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.13.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new stake in shares of PepGen during the third quarter valued at approximately $95,000. Suvretta Capital Management LLC increased its position in PepGen by 9.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock valued at $14,201,000 after acquiring an additional 140,000 shares during the period. Walleye Capital LLC acquired a new stake in PepGen in the 3rd quarter valued at approximately $519,000. Janus Henderson Group PLC raised its stake in PepGen by 331.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after acquiring an additional 1,794,641 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in PepGen by 76.9% during the 3rd quarter. Wellington Management Group LLP now owns 40,517 shares of the company’s stock worth $346,000 after acquiring an additional 17,618 shares during the period. Institutional investors own 58.01% of the company’s stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.